| __timestamp | Intra-Cellular Therapies, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 11768000 |
| Thursday, January 1, 2015 | 87718074 | 15152000 |
| Friday, January 1, 2016 | 93831530 | 19828000 |
| Sunday, January 1, 2017 | 79419009 | 25573000 |
| Monday, January 1, 2018 | 132166913 | 23634000 |
| Tuesday, January 1, 2019 | 89124838 | 38845000 |
| Wednesday, January 1, 2020 | 65782137 | 50523000 |
| Friday, January 1, 2021 | 88845513 | 75463000 |
| Saturday, January 1, 2022 | 134715000 | 105767000 |
| Sunday, January 1, 2023 | 180142000 | 167512000 |
Cracking the code
In the dynamic world of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Intra-Cellular Therapies, Inc. and Xenon Pharmaceuticals Inc. have been at the forefront of this evolution. From 2014 to 2023, Intra-Cellular Therapies has seen its R&D expenses grow by an impressive 750%, reflecting its commitment to pioneering treatments. Meanwhile, Xenon Pharmaceuticals has also demonstrated robust growth, with a 1,300% increase in R&D spending, underscoring its dedication to advancing neurological therapies.
The year 2023 marked a significant milestone, with Intra-Cellular Therapies investing 180 million USD, while Xenon Pharmaceuticals allocated 168 million USD to R&D. This trend highlights the increasing importance of R&D in driving therapeutic breakthroughs and maintaining competitive advantage in the biopharmaceutical industry. As these companies continue to innovate, their R&D investments will likely shape the future of healthcare.
Research and Development Investment: Zoetis Inc. vs Intra-Cellular Therapies, Inc.
Research and Development Expenses Breakdown: argenx SE vs Intra-Cellular Therapies, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Research and Development Investment: Genmab A/S vs Intra-Cellular Therapies, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Celldex Therapeutics, Inc.: Who Invests More in Innovation?
Bio-Techne Corporation vs Xenon Pharmaceuticals Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: PTC Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.
Who Prioritizes Innovation? R&D Spending Compared for Perrigo Company plc and Xenon Pharmaceuticals Inc.
Research and Development Expenses Breakdown: Xenon Pharmaceuticals Inc. vs Travere Therapeutics, Inc.